Fly News Breaks for April 21, 2015
INCY
Apr 21, 2015 | 05:57 EDT
Piper Jaffray raised its price target for Incyte to $121 citing the company's "evolving" pipeline following its analyst event. Piper notes the company will present data at ASCO for its combination JAK1/PI3K inhibitors for treatment of B-cell malignancies and is talking to the FDA regarding a pivotal trial in Hodgkin's lymphoma. It reiterates an Overweight rating on Incyte.
News For INCY From the Last 2 Days
There are no results for your query INCY